Treatment
Temozolomide clinical trials
We’re tracking 147 recruiting studies that include Temozolomide, each written for real people, not researchers, below.
Recruiting studies
- NCT06514313RecruitingPhase 2
Study of a drug combo for children with returning soft tissue sarcoma
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
Guangzhou, GuangdongAges 2–21 - NCT06546631Recruiting
Blood side effects of a chemotherapy for brain tumors
This study looks at why some people getting the chemotherapy drug temozolomide (TMZ) for high-grade brain tumors have serious blood side effects. If you are getting TMZ now or have had severe blood problems from it, your participation could help doctors predict and manage these risks better.
CorkAges 18 years+ - NCT06624644RecruitingPhase 2/Phase 3
LNS8801 with or without pembrolizumab for advanced melanoma
This trial tests a new drug called LNS8801, alone or with pembrolizumab, for people with advanced melanoma that has stopped responding to prior treatments, especially anti-PD-1 therapy.
Newport Beach, CaliforniaAges 18 years+ - NCT06630260RecruitingPhase 1/Phase 2
Avutometinib and Defactinib for brain tumors
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
CambridgeAges 16 years+ - NCT06649851RecruitingPhase 2
G-CSF to reduce side effects during glioblastoma treatment
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT06681220RecruitingPhase 1/Phase 2
Temozolomide and stenoparib for relapsed small cell lung cancer
This trial tests two drugs—temozolomide and stenoparib—for people with small cell lung cancer that has returned after initial chemo. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Palo Alto, CaliforniaAges 18 years+ - NCT06743126RecruitingPhase 3
IMA203 vs standard treatment for advanced skin cancer
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
Phoenix, ArizonaAges 18 years+ - NCT06831526RecruitingEarly Phase 1
Chemoradiation with or without azeliragon for new glioblastoma
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
St Louis, MissouriAges 18 years+ - NCT06850766Recruiting
Timing of chemotherapy (morning vs evening) for glioblastoma
This trial tests whether taking the chemotherapy drug temozolomide in the morning or in the evening works better and causes fewer side effects for people with a type of brain cancer called glioblastoma.
London, OntarioAges 18 years+ - NCT06934889RecruitingPhase 1
Study of ABBV-637 or ABBV-155 with ERAS-801 for recurrent glioblastoma
This trial tests two new drugs (ABBV-637 or ABBV-155) combined with ERAS-801 for people with recurrent glioblastoma (a type of brain cancer). It may help if your tumor has a specific genetic change (EGFR amplification) and you are having surgery to remove part of the tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT06942039RecruitingEarly Phase 1
Study of two drugs for young children with aggressive brain tumors
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
Calgary, AlbertaAges Up to 6 years - NCT06964815Recruiting
Silibinin plus standard treatment for newly diagnosed glioblastoma
This trial tests whether adding the supplement silibinin (milk thistle extract) to the usual radiation and chemotherapy can help people with a certain type of aggressive brain cancer live longer. The study is for patients whose tumor tests positive for a protein called STAT3 and whose cancer has not spread.
Bologna, BOAges 18–99 - NCT06995872RecruitingPhase 1
Study of rhIL-15 with immunotherapy and chemo for neuroblastoma
This trial tests a new combination of drugs (rhIL-15, dinutuximab, irinotecan, and temozolomide) for children and young adults whose neuroblastoma has come back or hasn't responded to other treatments. The goal is to see if this mix can help shrink or control the cancer.
Bethesda, MarylandAges 3–35 - NCT07015242RecruitingPhase 2
Liso-cel for newly treated primary CNS lymphoma
This trial tests a new cancer immunotherapy called liso-cel (a CAR T-cell treatment) as a first treatment for people with primary CNS lymphoma who cannot have a stem cell transplant. If you've already received some high-dose methotrexate and your tumor responded, this study may offer a more targeted therapy to try to improve results.
Aurora, ColoradoAges 18 years+ - NCT07193654RecruitingPhase 2
Combined stupp therapy and spinal chemo for advanced glioblastoma
This trial tests adding a chemotherapy drug (thiotepa) directly into the spinal fluid for people with a newly diagnosed glioblastoma that has spread to the brain's lining or ventricles. It aims to see if this extra treatment can help control the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07194044RecruitingPhase 1
Testing a treatment schedule for metastatic Ewing sarcoma
This trial tests a new schedule of standard chemotherapy drugs to see if it improves outcomes for people with metastatic Ewing sarcoma or CIC-rearranged sarcoma. It is for patients who have not had prior cancer treatment, except possibly one initial cycle of VDC.
Birmingham, AlabamaAges 1 year+ - NCT07223034RecruitingPhase 1
A study of targeted radiation for PSMA-positive gliomas
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
Basking Ridge, New JerseyAges 18 years+ - NCT06541262RecruitingPhase 1/Phase 2
Silmitasertib plus chemo for relapsed solid tumors
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Birmingham, AlabamaAges Up to 30 years - NCT07297212RecruitingPhase 2
Testing the drug pumitamig for recurrent glioblastoma
This trial tests an investigational drug called pumitamig (also known as BNT327) in people whose glioblastoma has come back after standard treatment with radiation and temozolomide. The goal is to see if the drug is safe and whether it can help slow or stop tumor growth.
BeijingAges 18–75 - NCT07334301RecruitingPhase 1/Phase 2
Combination treatments for relapsed high-risk neuroblastoma
This trial is testing different combinations of medicines for children with high-risk neuroblastoma that has come back. It has two paths: one for children whose disease has relapsed only once, and another for those whose disease has come back more than once. The goal is to find which treatments work best.
SydneyAges 1 year+ - NCT06805305RecruitingPhase 2
Immunotherapy for newly diagnosed glioblastoma
This trial tests a new personalized immunotherapy (DOC1021) for people with newly diagnosed glioblastoma. The treatment uses your own immune cells to attack the tumor and is given after surgery and with standard chemotherapy and radiation.
Gilbert, ArizonaAges 18 years+ - NCT07391215RecruitingPhase 1/Phase 2
Paxalisib for newly diagnosed glioblastoma after standard treatment
This trial tests a drug called paxalisib in people with a newly diagnosed aggressive brain tumor (glioblastoma) who have just finished standard radiation and chemotherapy. The goal is to see if adding paxalisib can help prevent the tumor from coming back by targeting a specific pathway in the cancer cells.
SuttonAges 16 years+ - NCT01356290RecruitingPhase 2
Anti-cancer blood-vessel treatment for relapsed childhood brain tumors
This trial tests a treatment that targets tumor blood-vessel growth to slow or shrink relapsed/progressive brain tumors in children. It may help if standard options are no longer working.
Chicago, IllinoisAges Up to 19 years - NCT07476794RecruitingPhase 2
Daily temozolomide for elderly patients with newly diagnosed brain cancer
This trial tests a daily chemo drug (temozolomide) in patients aged 65 or older with a specific type of aggressive brain cancer that has a certain genetic marker. It aims to see if this daily schedule works well after initial radiation and chemo.
Toronto, OntarioAges 65 years+
Common questions
- Are there clinical trials studying Temozolomide?
- Yes. Clin2 currently lists 147 recruiting studies that include Temozolomide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Temozolomide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Temozolomide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Temozolomide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.